CN1278727C - Colonitis enteroclysm - Google Patents
Colonitis enteroclysm Download PDFInfo
- Publication number
- CN1278727C CN1278727C CNB031013198A CN03101319A CN1278727C CN 1278727 C CN1278727 C CN 1278727C CN B031013198 A CNB031013198 A CN B031013198A CN 03101319 A CN03101319 A CN 03101319A CN 1278727 C CN1278727 C CN 1278727C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- weight portion
- colonitis
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007920 enema Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 206010009887 colitis Diseases 0.000 claims description 14
- 241000792859 Enema Species 0.000 claims description 12
- 229940095399 enema Drugs 0.000 claims description 12
- 239000009806 pulsatillae Substances 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 8
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 208000008710 Amebic Dysentery Diseases 0.000 abstract description 3
- 206010001986 Amoebic dysentery Diseases 0.000 abstract description 3
- 208000004429 Bacillary Dysentery Diseases 0.000 abstract description 3
- 206010017915 Gastroenteritis shigella Diseases 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 3
- 201000005113 shigellosis Diseases 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 230000023597 hemostasis Effects 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 abstract 1
- 235000016993 Agrimonia Nutrition 0.000 abstract 1
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 241001313857 Bletilla striata Species 0.000 abstract 1
- 241000202807 Glycyrrhiza Species 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 240000001090 Papaver somniferum Species 0.000 abstract 1
- 235000008753 Papaver somniferum Nutrition 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 241000206469 Pulsatilla Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 241001534869 Terminalia Species 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 244000144980 herd Species 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- NBSRUZQXRUNPNY-FOCLMDBBSA-N NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound NS(=O)(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O NBSRUZQXRUNPNY-FOCLMDBBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000629 anti-dermatophyte Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008351 salazosulfamide Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an enteroclysis agent for treating colonitis, which is prepared from the following raw material or the water and/or alcohol extract of the following raw material as active ingredients by weight parts: 11 to 13 parts of hairyvein agrimonia herd, 14 to 16 parts of Chinese pulsatilla root, 14 to 16 parts of phellodendron bark, 11 to 13 parts of lithospermum root, 8 to 10 parts of lightyellow sophora root, 9 to 11 parts of radix glycyrrhiza root, 2 to 4 parts of poppy shell, 14 to 16 parts of tuber of hyacinth bletilla, 5 to 7 parts of medicine terminalia fruit and 2 to 4 parts of clove. The combined formula has the functions of sterilization, detoxification, slough elimination, granulation promotion, hemostasis, diarrhea stop and pain alleviation, and is mainly used for treating chronic colonitis, chronic ulcerative colonitis, chronic bacillary dysentery and amebic dysentery.
Description
Technical field
The invention belongs to a kind of Chinese herbal medicine for external use prescription, particularly a kind of colitis enema.
Background technology
Chronic colitis is a commonly encountered diseases, and internal medicine does not still have the specific drug treatment at present.Treatment prescription about chronic colitis in the Chinese patent application bulletin has several, but great majority belong to oral formulations, wherein " enema treatment chronic colitis Chinese medicine preparation " (CN1176805) disclose a kind of with Pericarpium Granati, the Radix Stemonae, Galla Chinensis, the Radix Pulsatillae, the Pseudobulbus Bletillae (Rhizoma Bletillae), Radix Et Rhizoma Rhei, red paraffin wax, drug powders such as Alumen add that an amount of water and Amylum Nelumbinis Rhizomatis carry out the medicament of enema treatment, the Chinese patent Chinese patent medicine preparation and the preparation method of chronic colitis clinical syndrome " treatment " (CN1165008) disclose a kind of with Radix Sophorae Flavescentis, Folium Eucalypti Robustae, Indigo Naturalis, the enema that Margarita layer powder etc. are made, more than inorganic salts substances is all arranged in the prescription of two patent applications, still have many precipitate after particularly Indigo Naturalis is fried in shallow oil, some component for treating DeGrain, and in processing and the use inconvenience is arranged all.
Summary of the invention
The purpose of this invention is to provide a kind of evident in efficacy, using method simple, be the colitis enema of Main Ingredients and Appearance with pure medical herbs or its extract.
Purpose of the present invention realizes by following scheme:
A kind of colitis enema, it is made up of following raw materials according or is made up of as active ingredient the water and/or the alcohol extract of following raw materials according: Herba Agrimoniae 11-13 weight portion, Radix Pulsatillae 14-16 weight portion, Cortex Phellodendri 14-16 weight portion, Radix Arnebiae (Radix Lithospermi) 11-13 weight portion, Radix Sophorae Flavescentis 8-10 weight portion, Radix Rubiae 9-11 weight portion, Pericarpium Papaveris 2-4 weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 14-16 weight portion, Fructus Chebulae 5-7 weight portion, Flos Caryophylli 2-4 weight portion.
The effect of each composition of the present invention is as follows:
Herba Agrimoniae: contain agrimonine, vitamin K etc., it can make clotting time shorten, and platelet increases, the treatment hemorrhage.To escherichia coli, bacillus pyocyaneus, dysentery bacterium, Bacillus typhi has inhibitory action.
The Radix Pulsatillae: contain Anemonin, analgesia, sedation are arranged, intestinal mucosa is had convergence, the antidiarrheal anastalsis, to amebic dysentery, bacillary dysentery and infusorian are all effective.
Cortex Phellodendri: Han Huang Tiller alkali, antibacterial action and Rhizoma Coptidis are roughly the same.Ameba, fungus there are antibacterial action, blood sugar lowering, blood pressure and the effect of protection platelet are arranged.
Radix Arnebiae (Radix Lithospermi): analgesic, hypotensive effect is arranged, but anti-dermatophyte.Obvious anti-pituitary gonadotropic hormone and anti-chorionic-gonadotropin hormone effect are arranged.To chorionic epithelioma, women's menopause syndrome also has effect.
Radix Sophorae Flavescentis: contain matrine, antibacterial bacteriostatic is arranged, anticancer, strengthen effects such as body immunity.
Radix Rubiae: the effect of the clotting time of shortening is arranged, effective to the purple hall of anaphylaxis.Golden Portugal bacterium, Diplococcus pneumoniae there are inhibitory action, jaundice eliminating heat clearing away effect is arranged.
Pericarpium Papaveris: contain morphine, narcotine, codeine and papaverine etc., relieving diarrhea with astringents, analgesic effect are arranged.
The Pseudobulbus Bletillae (Rhizoma Bletillae): contain Pseudobulbus Bletillae (Rhizoma Bletillae) colloid, Glan Albert'stain Albert negative bacterium, tubercule bacillus are had inhibitory action, this product can make hemagglutination, forms artificial thrombosis, and haemostatic effect is determined rapidly.Endogenous toxin to some bacillus have inhibitory action.
Fructus Chebulae: contain and scold multitude's acid, tannin, fatty oil, oxidation gallic acid etc.Experiment in vitro has stronger bacteriostasis to diphtheria corynebacterium, dysentery bacterium, Diplococcus pneumoniae, bacillus pyocyaneus; Golden Portugal bacterium, Bacillus proteus, typhoid fever, Salmonella paratyphi also there are inhibitory action, and astriction is arranged.
Flos Caryophylli: contain caryophyllin, the volatilization wet goods.Staphylococcus aureus, diphtheria corynebacterium, Bacillus typhi, dysentery bacterium, anthrax bacillus etc. there are inhibitory action, can wriggle by stimulating gastrointestinal, impel gastric secretion.Pharmacological evaluation: it has antihistaminic, reduces capillary permeability, and the microcirculation improvement effect has convergence simultaneously, the repercussive effect.
Have the effect of sterilization detoxifcation, removing the necrotic tissue and promoting granulation, hemostasis antidiarrhea and analgesic after the above prescription combination, cure mainly chronic colitis, chronic ulcerative colitis, chronic bacillary dysentery and amebic dysentery.
The present invention press formula ratio decocting secondary in when treatment, and each extracting juice 200ml mixing divides sooner or later retention enema after each half temperature, gets buttocks and raises position, and the whole absorptions of medicinal liquid are not discharged, and 15 days is a course of treatment, and general treatment 2-3 course of treatment, per course of treatment, the interval was 3-5 days.
Therapeutic effect:
1. case is selected: divide treatment group and matched group, the treatment group is treated as stated above with the present invention, and matched group is given oral Berberine Tablet, norfloxacin or salazosulfamide sheet.
164 examples are organized in treatment, man's 85 examples, women 76 examples, age 18-72 year, average 48.2 years old, sick 1 year to 28.4 age, average 5.5 years, symptom has all repeatedly that lower abdomen is painful, abdominal distention, Mucous Stool or loose stool replace with constipation, and it is dissatisfied and go to a doctor often to take various western medicines in treatment curative effects, and all cases are used fibercolonscopy before treating, be diagnosed as chronic colitis, wherein chronic ulcerative colitis 54 examples, chronic non-ulcerative colitis 110 examples.
Matched group all through fibercolonscopy, is diagnosed as chronic colitis before all cases are treated by establishing 82 examples with the treatment group by 1: 2 randomized, ulcerative colitis 28 examples wherein, non-ulcerative colitis 54 examples.
2. therapeutic effect:
Curative effect determinate standard: a. cures: clinical symptom disappearance, and molding every day soft stool 1-2 time, the splanchnoscopy intestinal mucosa is normal.
B. produce effects: symptom is clearly better, and the splanchnoscopy extent of disease dwindles than originally more than 50% and (comprises 50%).
C. take a turn for the better: doing well,improving, the splanchnoscopy pathological changes is dwindled below 50%.
D. invalid: symptom does not have improvement, and splanchnoscopy does not have improvement.
After treatment, 164 examples are organized in treatment, cure 68 examples (41.46%), and wherein the ulcerative colitis cure rate reaches 64.8%, produce effects 42 examples (25.60%), 48 examples that take a turn for the better (29.26%), invalid 6 examples (3.65%); Total effective rate reaches 96.35%.
Matched group 82 examples, cure 11 examples (13.4%), wherein the ulcerative colitis cure rate 28.57%, produce effects 14 examples (17.07%), 37 examples that take a turn for the better (45.12%), invalid 20 examples (24.39%), total effective rate 75.60%, treatment group and matched group cure rate, total effective rate are added up and handled, utmost point significant difference is arranged.
Example surplus the clinical cure chronic colitis patient 1000 up to now.
The specific embodiment
Press routine prescription and prepare enema of the present invention: Herba Agrimoniae 12g, Radix Pulsatillae 15g, Cortex Phellodendri 15g, Radix Arnebiae (Radix Lithospermi) 12g, Radix Sophorae Flavescentis 9g, licorice 10g, Pericarpium Papaveris 3g, Pseudobulbus Bletillae (Rhizoma Bletillae) 15g, Fructus Chebulae 6g, Flos Caryophylli 3g, after the pack auxiliary medicine, usage: each a bag, dissolve in 200 milliliters in the eliminating cold for resuscitation water, get buttocks and raise a retention enema, per 15 days is a course of treatment.
Make instant sugar free granule after also can enlarging by said ratio, it is for household use to be equipped with little enemator, and also available general infusion set is coloclysis within the family.
Claims (2)
1, a kind of colitis enema, the active component that it is characterized in that it is to be made by following raw materials according: Herba Agrimoniae 11-13 weight portion, Radix Pulsatillae 14-16 weight portion, Cortex Phellodendri 14-16 weight portion, Radix Arnebiae (Radix Lithospermi) 11-13 weight portion, Radix Sophorae Flavescentis 8-10 weight portion, Radix Rubiae 9-11 weight portion, Pericarpium Papaveris 2-4 weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 14-16 weight portion, Fructus Chebulae 5-7 weight portion, Flos Caryophylli 2-4 weight portion.
2, colitis enema as claimed in claim 1 is characterized in that each proportion of raw materials is: Herba Agrimoniae 12 weight portions, the Radix Pulsatillae 15 weight portions, Cortex Phellodendri 15 weight portions, Radix Arnebiae (Radix Lithospermi) 12 weight portions, Radix Sophorae Flavescentis 9 weight portions, licorice 10 weight portions, Pericarpium Papaveris 3 weight portions, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 weight portions, Fructus Chebulae's 6 weight portions, Flos Caryophylli 3 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031013198A CN1278727C (en) | 2003-01-02 | 2003-01-02 | Colonitis enteroclysm |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031013198A CN1278727C (en) | 2003-01-02 | 2003-01-02 | Colonitis enteroclysm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1429613A CN1429613A (en) | 2003-07-16 |
| CN1278727C true CN1278727C (en) | 2006-10-11 |
Family
ID=4789940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031013198A Expired - Fee Related CN1278727C (en) | 2003-01-02 | 2003-01-02 | Colonitis enteroclysm |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1278727C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579825A (en) * | 2012-02-24 | 2012-07-18 | 北京市肛肠医院 | Compound hyacinth bletilla enema |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101393825B1 (en) * | 2012-07-03 | 2014-05-12 | 경희대학교 산학협력단 | Pharmaceutical composition for preventing or treating inflammatory bowel disease comprising extract of root of Stemona japonica Miquel |
| CN105168399A (en) * | 2015-09-21 | 2015-12-23 | 青岛金智高新技术有限公司 | Clysis fluid for treating chronic non-specific ulcerative colitis |
| CN105535893A (en) * | 2015-12-31 | 2016-05-04 | 刘婵琳 | Traditional Chinese medicine enema for treating colonitis |
| CN116966188A (en) * | 2023-07-14 | 2023-10-31 | 天津医科大学总医院 | Application of syringin in preparation of medicines for treating and/or preventing inflammatory bowel disease |
-
2003
- 2003-01-02 CN CNB031013198A patent/CN1278727C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579825A (en) * | 2012-02-24 | 2012-07-18 | 北京市肛肠医院 | Compound hyacinth bletilla enema |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1429613A (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167847B (en) | Traditional Chinese medicinal white spirit preparation for effectively treating skin disease | |
| CN105833279B (en) | External medicinal composition for treating various wounds of skin and preparation method thereof | |
| KR20240102982A (en) | Traditional Chinese herbal medicine for the treatment of hives, eczema, allergies/kinetic reactive constitution | |
| CN104127531A (en) | Traditional Chinese medicine composition for treating enterogastritis and preparation method thereof | |
| CN101366858B (en) | Preparation method of medicament for clearing heat, discharging fire, dispelling wind and relieving pain | |
| CN100444889C (en) | Chinese medicinal composition for treating mastopathy | |
| CN101244185A (en) | Chinese medicinal herb composition for treating skin disease and cloth containing the combination | |
| CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
| CN101732591B (en) | Sores plaster | |
| CN1278727C (en) | Colonitis enteroclysm | |
| CN101856481A (en) | Externally used ointment for dispersing swelling and dissipating binds | |
| CN1212127C (en) | Medicated sanitary article for treating gynopathy and its preparation | |
| CN1318052C (en) | Medicine compositions for treating acne, and its prepn. method | |
| KR20060033070A (en) | Suppositories for treating hemorrhoids or gynecological disorders | |
| CN102274353A (en) | Traditional Chinese preparation for treating ulcers | |
| CN1059801C (en) | Medicament for treating rheum | |
| CN1167453C (en) | A powder for the treatment of hemorrhoid | |
| CN1618439A (en) | Broad-specturm medicine for treating snake venom poisoning | |
| CN103169850A (en) | Mongolian medicine for treating peptic ulcer | |
| CN1238012C (en) | Chinese medicine in the form of spray for treating infection of tonsil | |
| CN103585597A (en) | Traditional Chinese medicine composition for relieving severe pain caused by renal calculus | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN101129997A (en) | Radix curcumae oral liquid for relieving exterior syndrome | |
| CN102198185B (en) | Medicament for rapidly treating chronic pharyngolaryngitis | |
| CN102018811A (en) | Chinese materia medica preparation for treating urticaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061011 Termination date: 20100202 |